Rituximab in ANCA-associated disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 37 citations in OpenAlex.

1. Lower Myeloperoxidase-ANCA Titres at Diagnosis Are Associated with End-Stage Kidney Disease Progression During Follow-Up in Rituximab-Treated Patients with Microscopic Polyangiitis.Medicina (Kaunas, Lithuania) · 2025
   Article
2. Current Understanding of the Pathogenesis of ANCA-Associated Vasculitis and Novel Treatment Options Targeting Complement Activation.Life (Basel, Switzerland) · 2025
   Review
3. Tofacitinib-Induced Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis With Crescentic Glomerulonephritis.Cureus · 2021
   Article
4. Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission.Internal medicine (Tokyo, Japan) · 2020
   Article
5. Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015
   Article
6. Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.ImmunoTargets and therapy · 2015
   Review
7. Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.PharmacoEconomics · 2014
   Article
8. Clinical features of childhood granulomatosis with polyangiitis (wegener's granulomatosis).Pediatric rheumatology online journal · 2014
   Article
9. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis.Annual review of pathology · 2013
   Review
10. Progressive dyspnoea following the treatment of Mycobacterium abscessus infection in an individual with relapsing granulamatosis with polyangitis (Wegener's), complicated by hearing loss requiring cochlear implantation.BMC pulmonary medicine · 2012
    Review
11. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).Arthritis research & therapy · 2011
    Article
12. Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis.Current opinion in nephrology and hypertension · 2011
    Review
13. Biologic agents in systemic vasculitis.International journal of clinical rheumatology · 2011
    Article

Corrections and comments

• Comment on
  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.2010
• Comment on
  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.2010
• Erratum issued

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as